Clinical study of autologous tumor tissue lysate loading dendritic cells for the treatment of hepatocellular carcinoma
- VernacularTitle:自体肿瘤组织致敏的树突状细胞瘤苗治疗肝癌的临床观察
- Author:
Dongyin LI
;
Chuan GU
;
Jun MIN
;
Zhonghua CHU
;
Qingjia OU
- Publication Type:Journal Article
- Keywords:
Hepatoeellular carcinoma;
Dendritic Cell;
Immunotherapy
- From:
Clinical Medicine of China
2008;24(7):693-696
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the feasibility and safety of autologous tumor tissue lysate loading den-dritic cells(DC) for the treatment of hepatocellular carcinoma (HCC). Methods The monocytes-derived DC were induced and antigen loaded with tumor tissue lysate to produce DC vaccine. Vaccination and clinical observation were conducted in 12 HCC patients for 41 times. Results The average output of DC was 1.69×107(1.69×107±9.44×106>) from 90 ml peripheral blood. 63.41% (26/41)patients appeared to develop delayed-type hypersensitivity after intradermal injection. After an average of 9 months follow up, 1 patient out of 4 recurrence and metastasis pa- tients survived for 17 months. The other three patients progressed. Out of 8 patients undergoing immunotherapy post- operatively,6 patients had no signs of recurrence and the others were found to have liver rceurrence and progression. Conclusion DC based immunotherapy is safe and feasible,with no side effects,which can be applied in the immu- notherapy strategy of HCC patients.
